ALXO

ALX ONCOLOGY HOLDINGS INC

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001810182 Biotech & Drug Discovery

$1.13 −0.04 (−3.42%)

Oct 26 4:00 PM ET · prev $1.17

Market cap

$148.7M

Micro cap

Median target

$4.00

+254% · range $4.00–6.00

Next earnings

Nov 5

in 10 days · EPS est. −$0.13

1 year

−33.5%

from $1.70 · Oct 27

30 days

−18.7%

from $1.39

52-week range

$0.8950–2.60

−57% from high · low Oct 14

Avg volume 20D

1.45M

Oct 15 spike 3.71M

Short interest

5.67M

≈4.1% of shares · −9.6%

Days to cover

3.8

at average volume

Insider net

+$5.0M

1 buyer · 3 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 5 reports · 90 days

Balance 0 bearish · 0 bullish · 2 mixed · 3 neutral oldest → newest, height = score

Avg score

·High conf. 1/5 ·Next Earnings date, Nov 5, 2026

Strongest MIXED ALX Oncology entered into exchange agreements with major stockholders (Blackstone, RA Capital, venBio) to…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B Feb 2 1 insider buy $5.0M at $1.57
S Feb 18 1 insider sell $1.3K at $2.27
A Mar 19 Wells Fargo initiates
S Mar 19 2 insiders sell $28.7K at $2.17
S Jul 1 1 insider sell $2.9K at $2.04
S Aug 17 2 insiders sell $5.4K at $1.93
E Sep 28 FDA: ALX Oncology Announces Nature Medicine Publication of ASPE…
R Oct 15 ALX Oncology entered into exchange agreements with major stockholder…

Signal stack

Where each data set points today.

InsidersBULLISH

1 insider bought $5.0M at an average $1.57. 3 insiders sold $38.2K. Price is 28% below their cost.
InstitutionsBULLISH

Q2 2026: 15 added (0 new), 3 trimmed or exited.
EstimatesRISING

Current-quarter EPS estimate −$0.149 → −$0.132 over 90 days. 4 up, 1 down in 30 days.
Short sellersSTEADY

Short interest −9.6% to 5.67M shares. 3.8 days to cover, ≈4.1% of shares.
TrendDOWNTREND

29% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
BlackRock, Inc.	DOUBLED	7,399,530	$15.3M
GEODE CAPITAL MANAGEMENT, LLC	DOUBLED	2,787,809	$5.8M
STATE STREET CORP	DOUBLED	1,498,905	$3.1M
JPMORGAN CHASE & CO	DOUBLED	1,044,728	$2.3M
NORTHERN TRUST CORP	DOUBLED	935,669	$1.9M
VANGUARD PORTFOLIO MANAGEMENT LLC	DOUBLED	749,229	$1.6M
VANGUARD FIDUCIARY TRUST CO	DOUBLED	743,491	$1.5M
GOLDMAN SACHS GROUP INC	DOUBLED	742,331	$1.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Mar 2026

12-month targets · 5 analysts

$1.13 $4.00 $4.00 $6.00

Price is below the lowest target. Median implies +254%.Targets as of Oct 26, 2026.

Recent actions

Date	Firm	Action	Rating
Mar 19, 2026	Wells Fargo INITIATE	INITIATE	Overweight
Mar 10, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy
Feb 5, 2026	Piper Sandler MAINTAIN	MAINTAIN	Overweight
May 21, 2025	UBS MAINTAIN	MAINTAIN	Buy
May 9, 2025	HC Wainwright & Co. MAINTAIN	MAINTAIN	Buy
Mar 7, 2025	Stifel MAINTAIN	MAINTAIN	Hold

Insider ledger

Form 4

$5.0M

bought · 1 insider

$38.2K

sold · 3 insiders

−28.0%

vs their $1.57 cost

Date	Insider	Type	Value
Aug 17, 2026	Wong Shelly SVP, FINANCE AND CAO	SELL	$1.1K
Aug 17, 2026	Lettmann Jason CHIEF EXECUTIVE OFFICER	SELL	$4.3K
Jul 1, 2026	Wong Shelly SVP, FINANCE AND CAO	SELL	$2.9K
Apr 16, 2026	Knight Jeff E. Chief Dev & Operating Officer	AWARD	800,000 sh
Apr 16, 2026	Klencke Barbara Chief Medical Officer	AWARD	100,000 sh
Mar 19, 2026	Lettmann Jason CHIEF EXECUTIVE OFFICER	SELL	$26.7K
Mar 19, 2026	Pinto Shelly SVP, FINANCE AND CAO	SELL	$2.0K
Mar 3, 2026	Klencke Barbara Chief Medical Officer	AWARD	700,000 sh

Earnings setup

Estimates

Nov 5

reports in 10 days

−$0.13

EPS estimate, this quarter

+12%

estimate change, 90 days

4↑ 1↓

revisions, 30 days

Current-quarter EPS estimate

−$0.149

90d

−$0.149

60d

−$0.132

30d

−$0.132

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.13	-$0.16–-$0.10	+0.0%	$0.00
Next Q	-$0.13	-$0.17–-$0.09	+0.0%	$0.00
Current FY	-$2.64	-$3.58–-$1.70	+0.3%	$0.00
Next FY	-$0.55	-$0.74–-$0.40	+0.0%	$0.00

Short side

FINRA· Sep 30, 2026

5,673,137

shares short

-9.6%

vs prior settlement

3.8

days to cover

≈4.1%

of shares outstanding

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 16, 2026 SEC

venBio Global Strategic Fund, L.P. filed Amendment No. 2 to its Schedule 13D on ALX Oncology Holdings Inc., reporting…

SC 13D/A — Impact 4/10

Oct 15, 2026 SEC

ALX Oncology entered into exchange agreements with major stockholders (Blackstone, RA Capital, venBio) to surrender…

8-K — Impact 6/10

Sep 28, 2026 Press

ALX Oncology published Phase 2 ASPEN-06 data in Nature Medicine, showing evorpacept plus TRP achieved 40.3% ORR vs…

Impact 5/10

Sep 28, 2026 FDA

ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for con

Aug 17, 2026 Insider

Wong Shelly sold 573 shares

SVP, FINANCE AND CAO @ $1.93 ($1.1K)

Aug 17, 2026 Insider

Lettmann Jason sold 2,230 shares

CHIEF EXECUTIVE OFFICER @ $1.93 ($4.3K)

Aug 15, 2026 SEC

Six mega-passive institutional investors (BlackRock, State Street, Geode, JPMorgan, Morgan Stanley, Citigroup)…

INST-CLUSTER — Impact 4/10

Jul 1, 2026 Insider

Wong Shelly sold 1,404 shares